DE10157290A1 - Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III - Google Patents

Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III

Info

Publication number
DE10157290A1
DE10157290A1 DE10157290A DE10157290A DE10157290A1 DE 10157290 A1 DE10157290 A1 DE 10157290A1 DE 10157290 A DE10157290 A DE 10157290A DE 10157290 A DE10157290 A DE 10157290A DE 10157290 A1 DE10157290 A1 DE 10157290A1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
fcrγ
iib
iii
sfcrgamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10157290A
Other languages
German (de)
English (en)
Inventor
Robert Huber
Peter Sondermann
Uwe Jacob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to DE10157290A priority Critical patent/DE10157290A1/de
Priority to DE50212814T priority patent/DE50212814D1/de
Priority to PCT/EP2002/013080 priority patent/WO2003043648A2/de
Priority to CA2506068A priority patent/CA2506068C/en
Priority to EP02803402A priority patent/EP1446139B1/de
Priority to ES02803402T priority patent/ES2309238T3/es
Priority to JP2003545329A priority patent/JP5414959B2/ja
Priority to AT02803402T priority patent/ATE409045T1/de
Priority to AU2002366200A priority patent/AU2002366200A1/en
Publication of DE10157290A1 publication Critical patent/DE10157290A1/de
Priority to US10/851,655 priority patent/US20050002924A1/en
Priority to CO04057552A priority patent/CO5590936A2/es
Priority to US11/971,438 priority patent/US20080214459A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE10157290A 2001-11-22 2001-11-22 Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III Withdrawn DE10157290A1 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE10157290A DE10157290A1 (de) 2001-11-22 2001-11-22 Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
ES02803402T ES2309238T3 (es) 2001-11-22 2002-11-21 Composicion farmaceutica que contiene el receptor fc gamma iib soluble.
PCT/EP2002/013080 WO2003043648A2 (de) 2001-11-22 2002-11-21 Sfcyr iib oder sfcyr iii für die behandlung von autoimmunkrankheiten
CA2506068A CA2506068C (en) 2001-11-22 2002-11-21 Pharmaceutical composition containing sfcyr iib or sfcyr iii
EP02803402A EP1446139B1 (de) 2001-11-22 2002-11-21 Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib
DE50212814T DE50212814D1 (de) 2001-11-22 2002-11-21 Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib
JP2003545329A JP5414959B2 (ja) 2001-11-22 2002-11-21 ｓＦｃγＲＩＩｂまたはｓＦｃγＲＩＩＩを含有する医薬品組成物
AT02803402T ATE409045T1 (de) 2001-11-22 2002-11-21 Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib
AU2002366200A AU2002366200A1 (en) 2001-11-22 2002-11-21 Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases
US10/851,655 US20050002924A1 (en) 2001-11-22 2004-05-24 Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III
CO04057552A CO5590936A2 (es) 2001-11-22 2004-06-18 Compuesto farmaceutico que contiene sfcyr iib o sfcyr iii
US11/971,438 US20080214459A1 (en) 2001-11-22 2008-01-09 Pharmaceutical composition containing sFcyRIIb

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10157290A DE10157290A1 (de) 2001-11-22 2001-11-22 Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III

Publications (1)

Publication Number Publication Date
DE10157290A1 true DE10157290A1 (de) 2003-06-05

Family

ID=7706571

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10157290A Withdrawn DE10157290A1 (de) 2001-11-22 2001-11-22 Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
DE50212814T Expired - Lifetime DE50212814D1 (de) 2001-11-22 2002-11-21 Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50212814T Expired - Lifetime DE50212814D1 (de) 2001-11-22 2002-11-21 Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib

Country Status (10)

Country Link
US (2) US20050002924A1 (https=)
EP (1) EP1446139B1 (https=)
JP (1) JP5414959B2 (https=)
AT (1) ATE409045T1 (https=)
AU (1) AU2002366200A1 (https=)
CA (1) CA2506068C (https=)
CO (1) CO5590936A2 (https=)
DE (2) DE10157290A1 (https=)
ES (1) ES2309238T3 (https=)
WO (1) WO2003043648A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004293184B2 (en) * 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
US10028998B2 (en) * 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
WO2014067959A1 (en) 2012-10-30 2014-05-08 Suppremol Gmbh A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease
AU2012244302B2 (en) * 2012-10-31 2014-08-21 Suppremol Gmbh A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2833139A1 (en) * 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN105873600B (zh) * 2013-10-16 2019-11-05 苏伯利莫尔公司 用于自身免疫性大疱病治疗的可溶性Fcγ受体
JP6893223B2 (ja) * 2013-10-16 2021-06-23 ズプレモル ゲーエムベーハー 医薬品組成物およびキット
JP2018050616A (ja) 2016-09-23 2018-04-05 東ソー株式会社 改良型組換えＦｃγＲＩＩ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291198A (zh) * 1998-02-06 2001-04-11 伊来克萨斯独资有限公司 Fc受体的三维结构和模型及其应用
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP1201681A1 (en) * 2000-10-30 2002-05-02 Millennium Pharmaceuticals, Inc. "Fail" molecules and uses thereof

Also Published As

Publication number Publication date
AU2002366200A8 (en) 2003-06-10
WO2003043648A2 (de) 2003-05-30
CO5590936A2 (es) 2005-12-30
JP5414959B2 (ja) 2014-02-12
AU2002366200A1 (en) 2003-06-10
EP1446139A2 (de) 2004-08-18
ATE409045T1 (de) 2008-10-15
JP2005515981A (ja) 2005-06-02
US20080214459A1 (en) 2008-09-04
WO2003043648A3 (de) 2004-01-08
DE50212814D1 (de) 2008-11-06
ES2309238T3 (es) 2008-12-16
CA2506068A1 (en) 2003-05-30
US20050002924A1 (en) 2005-01-06
EP1446139B1 (de) 2008-09-24
CA2506068C (en) 2011-09-20

Similar Documents

Publication Publication Date Title
DE69327582T2 (de) Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
DE69233643T2 (de) Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose
DE69312077T2 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE69835823T2 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon
DE60035057T2 (de) CD40 Antagonist zur Behandlung von Psoriasis
DE69724970T2 (de) Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a
DE60217698T2 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
DE3234947A1 (de) Arzneimittel zur behandlung von immundefektzustaenden
DE2415101A1 (de) Pharmazeutische zusammensetzungen
DE60034898T2 (de) Antiallergische Zusammensetzung, die OLIGOSACCHARIDe und eine Saponine oder eine basische Aminosäure enthält, zur topischen Verabreichung oder Inhalation
DE69827357T2 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
DE69528325T2 (de) Interleukin-6 Inhibitor aus Mensch
DE68908431T2 (de) Methode zur Verminderung der Immunglobulin-E-Reaktion.
DE10157290A1 (de) Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
CH650678A5 (de) Pharmazeutisches mittel aus human-insulin und human-proinsulin.
DE69116321T2 (de) Immunostimulierendes Mittel das Interleukin-2 und 5'-Deoxy-5-fluorouridin enthält
DE69904010T2 (de) Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
EP1516054A2 (de) Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
DE69533311T2 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69626050T2 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
DE69531166T2 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
DE102004042894A1 (de) Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
DE69525181T2 (de) Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
EP1850830B1 (de) Suppositorium zur bindung von reaktiven sauerstoffverbindungen im körper von menschen und tieren

Legal Events

Date Code Title Description
8141 Disposal/no request for examination